SLU-PP-332: Exercise Mimetic Research, Side Effects and Safety

What Is SLU-PP-332?

SLU-PP-332 is a laboratory-developed small molecule that belongs to a developing class of compounds called exercise mimetics. These compounds are studied because they may reproduce some of the cellular effects normally triggered by aerobic exercise. SLU-PP-332 was first described in a 2023 paper in ACS Chemical Biology by a research group led by Dr. Thomas P. Burris.

The name reflects its research origin. “SLU” refers to Saint Louis University, where early work on the compound series was performed. “PP” and “332” identify the compound, which has the molecular formula C18H14N2O2, within the laboratory’s naming system. Although many online sellers call it a peptide, that label is not chemically accurate.

SLU-PP-332 Is Not Actually a Peptide

Peptides are short chains of amino acids joined by peptide bonds. Examples include compounds such as BPC-157 or TB-500. SLU-PP-332 is different. It is a small organic molecule that binds to nuclear receptors. Its structure and mechanism are closer to drug-like receptor ligands than to true peptides.

The phrase “SLU-PP-332 peptide” is still common because many research-chemical suppliers group it with peptides for convenience. For scientific accuracy, it is better to describe SLU-PP-332 as a small-molecule ERR agonist.

Chemical Profile and Classification

SLU-PP-332 is classified as a pan-agonist of the estrogen-related receptor family. That means it can activate ERRα, ERRβ, and ERRγ. These receptors help regulate metabolism, mitochondrial function, fatty acid oxidation, and energy use in tissues such as skeletal muscle and heart.

The published mouse studies gave SLU-PP-332 by the intraperitoneal route, which is common in rodent work and says nothing about exposure by any other route or in any other species.

How Does SLU-PP-332 Work?

SLU-PP-332 works by activating estrogen-related receptors, especially ERRα. These receptors act as transcription factors, which means they help control which genes are turned on or off. When ERR signaling increases, cells may produce more proteins involved in mitochondrial activity, fat metabolism, and oxidative energy production.

What Are Estrogen-Related Receptors?

Estrogen-related receptors are named for their structural similarity to estrogen receptors, but they do not bind estrogen. They are involved mainly in energy metabolism and overall metabolic health. ERRα is highly expressed in tissues that need large amounts of energy, including skeletal muscle, heart, kidney, and brown fat.

ERRγ is especially important in the heart and brain. ERRβ is less studied but also plays roles in development, muscle function, and tissue function. Because SLU-PP-332 activates all three receptor subtypes, its effects may vary across tissues.

The Activation Cascade

After SLU-PP-332 binds to an ERR receptor, the receptor can recruit coactivator proteins such as PGC-1α. PGC-1α is often called a master regulator of mitochondrial biogenesis because it helps cells build more mitochondria and improve oxidative metabolism and mitochondrial respiration.

This process can increase genes involved in fatty acid oxidation, oxidative phosphorylation, and muscle endurance. In practical terms, the treated cells begin to resemble cells that have adapted to endurance training. This is why the compound is described as an exercise mimetic.

Orphan receptors that answer to coactivators

ERRα, ERRβ and ERRγ were the first orphan nuclear receptors to be identified, and none of them has yet been matched to a natural ligand (Audet-Walsh et al. 2015). Their regulation is therefore unusual. Rather than switching on when a hormone arrives, their transcriptional activity follows the supply of coregulator proteins that control energy homeostasis, and Giguère wrote in 2008 that these coregulators function, for all intents and purposes, as protein ligands for the ERRs (Giguère 2008). Functional genomics and biochemical studies showed ERRα and ERRγ acting as the primary conduits for the PGC-1 family of coactivators (Giguère 2008).

Through those partners the ERRs control large gene networks covering fat and glucose metabolism and mitochondrial biogenesis and function (Giguère 2008). Knockout mice showed that all three receptors are needed for normal development or for survival under a range of physiological challenges (Giguère 2008). Audet-Walsh and Giguère described the ERRs in 2015 as occupying a strategic node in the transcriptional control of energy metabolism, required when an organism meets challenges that demand high energy, with particular attention to liver and skeletal muscle (Audet-Walsh et al. 2015). They also discussed possible links to type 2 diabetes and metabolic syndrome, and the pitfalls as well as the promise of treating the ERRs as drug targets (Audet-Walsh et al. 2015). Synthetic ERRα agonists in particular had proved hard to design, which is the gap SLU-PP-332 was reported to fill in 2023 (Billon et al. 2023).

Why Is SLU-PP-332 Called an “Exercise in a Pill”?

The phrase “exercise in a pill” is catchy, but it can be misleading. SLU-PP-332 does not reproduce everything exercise does. Instead, it appears to mimic a specific part of exercise biology: the metabolic and mitochondrial signaling that helps muscles use energy more efficiently.

What Exercise Does to Cells

During aerobic exercise, muscle cells experience increased energy demand. ATP is used quickly, calcium signaling changes, and several stress-response pathways are activated. Over time, these signals increase mitochondrial density, improve fatty acid oxidation, and shift some muscle fibers toward a more fatigue-resistant profile.

How SLU-PP-332 Shortcuts Part of That Process

SLU-PP-332 appears to enter the process downstream by directly activating ERR-dependent gene programs. In mice, this led to greater oxidative muscle fiber formation, improved fatigue resistance, and a large increase in treadmill endurance. However, these findings are still limited to preclinical research.

What SLU-PP-332 Cannot Replace

Real exercise does much more than change metabolism. It strengthens bones, improves coordination, supports mental health, benefits the immune system, and improves cardiovascular conditioning through mechanical and circulatory stress. SLU-PP-332 cannot reproduce all of these effects.

The compound is best understood as a partial metabolic exercise mimetic, not a full replacement for physical activity.

What preclinical studies of SLU-PP-332 found

The possible benefits of SLU-PP-332 come from animal and cell studies. No human trial has confirmed whether these effects occur in people. The evidence is still early, but several findings have attracted attention.

Treadmill endurance in mice

In a 2023 mouse study, SLU-PP-332 increased treadmill running distance by about 70%. The researchers linked this effect to ERRα activation and a shift toward more oxidative, fatigue-resistant muscle fibers.

Reduced Fat Mass in Obese Mice

In a 2024 metabolic syndrome study, diet-induced obese mice models of obesity treated with SLU-PP-332 lost about 12% of body weight over 28 days. The weight lost came from fat mass, not lean mass. Food intake and activity levels did not significantly change, suggesting that the compound altered fuel use rather than simply reducing appetite.

Glucose tolerance in obese mice

The same study reported improved glucose metabolism, tolerance, and insulin sensitivity in obese mice, which are key markers in the study of metabolic diseases. This may relate to changes in fatty acid metabolism and metabolic flexibility. Still, these findings do not establish SLU-PP-332 as a diabetes treatment.

Cardioprotection in Heart Failure Models

A 2024 Circulation study found that SLU-PP-332 and the related compound SLU-PP-915 improved several markers of heart function in mice with pressure-overload heart failure. Treated mice had better ejection fraction, less fibrosis, and improved survival compared with controls.

SLU-PP-332 vs. Other Exercise Mimetics

SLU-PP-332 is one of several compounds studied for exercise-mimicking effects. Others include Cardarine, SR9009, AICAR, 5-amino-1mq, and SLU-PP-915. Each compound works through a different pathway, so they should not be treated as interchangeable.

Comparison With Cardarine

Cardarine and SLU-PP-332 are both discussed as endurance-related research compounds that influence lipid metabolism, but they target different receptors. Cardarine activates PPARδ, while SLU-PP-332 activates ERR receptors. Cardarine’s development was halted after tumor findings in animal studies. SLU-PP-332 has not shown the same published carcinogenicity signal, but long-term cancer-risk studies have not been completed.

Comparison With SLU-PP-915

SLU-PP-915 is a newer compound from the same general research area. It was designed to improve potency and oral activity. In some preclinical heart failure work, SLU-PP-915 appeared stronger than SLU-PP-332. Both remain investigational.

What the preclinical studies measured

There is no established human amount for SLU-PP-332. No Phase I safety trial has been completed, and no regulatory agency has approved the compound for medical use. All of the published work is in mice, using the intraperitoneal route: exercise capacity and muscle fibre type in the 2023 study, body weight, fat mass and glucose handling in diet-induced obese mice over 28 days in the 2024 metabolic syndrome study, and heart function, fibrosis and survival over six weeks in the 2024 pressure-overload heart failure study.

SLU PP 332 Side Effects and Safety Profile

The most accurate answer is that SLU PP 332 side effects in humans are unknown. No published human trial has tested the compound, so there is no reliable human safety profile, no established adverse-event rate, and no confirmed long-term risk assessment.

What Animal Studies Reported

In published mouse studies, researchers generally reported no obvious toxicity at the tested doses. In the six-week heart failure study, the authors stated that no overt toxicity was observed. Other studies reported no major changes in food intake, locomotor activity, or lean body mass.

These findings are encouraging, but they are limited. A six-week mouse study cannot rule out human side effects, rare adverse reactions, fertility effects, organ toxicity, cancer risk, or risks from chronic use.

Theoretical Side Effects and Concerns

Because SLU-PP-332 activates metabolic pathways, several theoretical concerns remain. Long-term activation of mitochondrial and fatty acid oxidation programs could affect oxidative stress. ERR receptors are present in many tissues, so effects may not be limited to skeletal muscle. The compound may also influence gene expression in ways that are not fully understood.

Another concern is formulation. Published animal studies used solvents such as DMSO and Cremophor-based vehicles. These are useful in laboratory research but are not automatically suitable for human use. A different formulation could change absorption, exposure, and toxicity.

Unknown Long-Term Risks

Long-term carcinogenicity studies, reproductive toxicity studies, and chronic organ-safety studies have not been published for SLU-PP-332. This is important because other exercise-mimetic compounds, most notably Cardarine, showed promising early metabolic effects but later raised serious long-term safety concerns in animal studies.

SLU-PP-332 in heart failure research

The 2024 Circulation study is one of the most important papers on SLU-PP-332. Researchers tested ERR agonists in a mouse model of pressure-overload heart failure. Both SLU-PP-332 and SLU-PP-915 improved several markers of heart function.

The treated mice showed better ejection fraction, less cardiac fibrosis, improved mitochondrial structure, and improved survival compared with untreated controls. The authors concluded that ERR agonism may be a promising direction for future heart failure therapy.

However, this does not mean SLU-PP-332 is an approved or proven heart failure treatment. The findings remain preclinical and must be tested in formal human trials before clinical conclusions can be made.

Is SLU-PP-332 Banned?

Yes. SLU-PP-332 is prohibited by the World Anti-Doping Agency under category S4, which covers hormone and metabolic modulators. The ban applies both in competition and out of competition.

For athletes subject to drug testing, use of SLU-PP-332 could result in an anti-doping violation. Detection methods for SLU-PP-332 and related metabolites have already been studied for doping-control purposes.

United States Legal Status

In the United States, SLU-PP-332 is not approved by the FDA for medical use and is not a dietary supplement. It may be sold only as a research chemical for laboratory purposes. It should not be marketed for human consumption.

Buying SLU-PP-332 for Research: What to Look For

Researchers who handle SLU-PP-332 should focus on purity, identity confirmation, and documentation. A reputable supplier should provide a batch-specific certificate of analysis that includes HPLC purity and mass spectrometry identity confirmation.

Proper labeling should clearly state that the compound is for research use only and not for human consumption. Storage should follow supplier guidance, generally in a cool, dry, dark environment, with refrigeration or freezing used for longer-term storage when appropriate.

Key Takeaways

SLU-PP-332 is one of the most interesting exercise-mimetic compounds in preclinical research. It activates ERR receptors and has produced notable effects in mice, including improved endurance, reduced fat mass, improved metabolic markers, and cardioprotective effects in a heart failure model.

The safety picture is much less certain. SLU PP 332 side effects in humans are unknown because no human trials have been published. Short-term animal studies reported no overt toxicity, but this does not prove long-term safety or human tolerability.

For now, SLU-PP-332 should be treated as an investigational research compound. Its scientific value is clear, but medical claims, human dosing claims, and human safety claims remain unsupported until clinical trials are completed.